SCHEMBL29655815

SCHEMBL29655815

CC(C)NC(=O)c1ccc2c(c1)C1(CCO2)CC1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.47
TAS1R3 Q7RTX0 6/20 0.46
TAS1R1 Q7RTX1 6/20 0.46
CYP26A1 O43174 1/20 0.45
CYP26B1 Q9NR63 1/20 0.45
PTGER4 P35408 1/20 0.45
RARA P10276 2/20 0.43
RARB P10826 2/20 0.43
RARG P13631 2/20 0.43
GAA P10253 1/20 0.42
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PDK2 Q15119 1/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29655711 0.88 SMN1; SMN2 (0.52) SMN1; SMN2TAS1R3TAS1R1CYP26A1CYP26B1
SCHEMBL29696137 0.85 CYP26A1 (0.47) SMN1; SMN2CYP26A1CYP26B1PTGER4RARA
SCHEMBL30353262 0.80 KDM4E (0.54) CYP26A1CYP26B1RARARARBRARG
SCHEMBL25029929 0.80 PTGER4 (0.58) TAS1R3TAS1R1CYP26A1CYP26B1PTGER4
SCHEMBL30181635 0.80 PTGER4 (0.58) TAS1R3TAS1R1CYP26A1CYP26B1PTGER4
SCHEMBL25029928 0.80 PTGER4 (0.58) TAS1R3TAS1R1CYP26A1CYP26B1PTGER4
SCHEMBL29655717 0.80 NPC1 (0.61) SMN1; SMN2PTGER4GAANPC1RAB9A
SCHEMBL29655774 0.79 NPC1 (0.56) SMN1; SMN2PTGER4GAANPC1RAB9A
SCHEMBL30353220 0.79 RARA (0.54) CYP26A1CYP26B1RARARARBRARG
SCHEMBL28347731 0.79 RARA (0.54) CYP26A1CYP26B1RARARARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022102731-A1 CANCER TREATMENT BY COMBINED USE OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR 小野薬品工業株式会社 2022-05-19 WO disclosed